Reengineering cancer vaccines for durable immune memory Therapeutic cancer vaccines are being reengineered to deliver stronger immune activation and longer-lasting protection against disease recurrence. Written byBree Foster, PhD

https://www.drugdiscoverynews.com/reengineering-cancer-vaccines-for-durable-immune-memory-17293?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_w6QR66mPoj9xCFxCKflFWaGdfRHmWRG_Ievh3ZnNTiVHMxpnSvjWRmgW9TEN0ZBwRL6DIyuhz4ldcKfXjaQBn_DB72g&_hsmi=426335944&utm_content=426335944&utm_source=hs_email When most people think of vaccines, they think of prevention — an injection that trains the immune system to produce antibodies against infectious diseases such as measles or polio. However, cancer vaccines are different. Rather than preventing disease, cancer vaccines are a type of immunotherapy designed to stimulate the immune system to attack cancer cells that are already present in the body. However, they have historically struggled to deliver consistent clinical benefit.